室间隔消融与保守药物治疗对梗阻性肥厚型心肌病患者疗效比较
该回顾性研究纳入北京安贞医院2002年9月至2014年9月住院的350例梗阻性肥厚型心肌病患者,比较室间隔消融(SA,n=184)与保守药物治疗(CM,n=184)对血流动力学、临床状态及生存的影响。中位随访4年(1-14年),SA组年死亡率2.4%高于CM组0.6%(P<0.001),但SA组累积心脏性猝死率3.61%(6/166)高于CM组0.54%(1/184)(P=0.031)。SA可显著降低左心室流出道压差并改善心功能。
要点
- SA组年死亡率2.4%高于CM组0.6%(P<0.001)。
- SA组累积心脏性猝死率3.61%(6/166)高于CM组0.54%(1/184)(P=0.031)。
核心结论
- SA可显著改善药物难治性HOCM患者的血流动力学和临床状态。
- 与接受CM的患者相比,SA组总体生存率显著更高,且不增加SCD风险。
研究设计与样本
- 回顾性研究,纳入北京安贞医院2002年9月至2014年9月住院的350例梗阻性肥厚型心肌病患者(平均年龄(51.3±13.5)岁)。
- 患者随访至14年,随访率99.4%(348/350)。
- 比较SA组(n=184)与CM组(n=184)的总体死亡率和心脏相关死亡率。
- 采用Cox回归分析评估临床事件的预测因素,Kaplan-Meier生存分析比较两组总死亡率,log-rank检验比较生存曲线差异。
主要发现
- 中位随访4年(1-14年),SA组和CM组年死亡率分别为2.4%和0.6%(P<0.001)。
- SA组和CM组累积心脏性猝死率分别为3.61%(6/166)和0.54%(1/184)(P=0.031)。
- 多因素回归分析显示年龄是总体死亡率最重要的独立预测因素(HR=1.259,95%CI 1.101-1.438,P=0.001)。
- SA后NYHA心功能分级由基线2.97±0.29改善至1.74±0.53(P<0.001)。
临床怎么用
- 作者认为SA可显著改善药物难治性HOCM患者的血流动力学和临床状态。
- 作者认为与CM相比,SA组总体生存率显著更高且不增加SCD风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To compare the effects of septal ablation (SA) versus conservative medication (CM) on the hemodynamic, clinical status and survival in patients with hypertrophic obstructive cardiomyopathy (HOCM). Methods: This retrospective study included 350 consecutive patients with HOCM (mean age (51.3±13.5) years old) hospitalized in Anzhen Hospital between September 2002 to September 2014. The patients were followed up to 14 years and the follow up rate was 99.4% (348/350). Overall and cardiac-related mortalities were compared between SA group (n=184) and CM group (n=184). Moreover, SA related cardiac function and hemodynamics improvement were also evaluated, predictors for clinical events were evaluated by Cox regression analysis and Kaplan-Meier survival analysis was used to compare the total mortality between the two groups. The log-rank test was used to compare the survival curve differences between the two groups. Results: The median follow-up period was 4 years (1-14 years). The annual mortalities of SA and CM were 2.4% and 0.6% respectively (P<0.001) and cumulative sudden cardiac death (SCD)rates were 3.61% (6/166) and 0.54% (1/184) respectively (P=0.031). Multivariate regression analysis demonstrated that the age was the most important independent predictor for overall mortality(HR=1.259, 95%CI 1.101-1.438, P=0.001). In addition, left ventricular outflow tract (LVOT) gradient was significantly reduced post SA (peak velocity of LVOT: baseline (4.23±1.05) m/s, post SA: (1.83±0.79) m/s, P<0. 01) and heart function was also significantly improved post SA (NYHA at baseline: 2.97±0.29, post SA: 1.74±0.53, P<0.001). Conclusion: SA could significantly improve the hemodynamics and clinical status in drug-resistant patients with HOCM. In comparison to patients received CM, overall survival rate was significantly higher in SA group without extra risk of SCD.
引用
- Zhao H, He JQ, Jiang B, et al. [Efficacy comparison between conservative therapy and septal ablation in patients with hypertrophic obstructive cardiomyopathy]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016. PMID: 28056231. doi:10.3760/cma.j.issn.0253-3758.2016.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。